The activator of histone acetyltransferases CBP/p300 is capable of passing the blood–brain barrier and extending the recent memory duration in B57BL6/6J male mice in vivo, which may be a potential treatment target in AD (174). This evidence concerns the gene CREBBP and Alzheimer disease.